

# Reninâ€™Angiotensinâ€™Aldosterone System Blockers a

New England Journal of Medicine

382, 2431-2440

DOI: [10.1056/nejmoa2006923](https://doi.org/10.1056/nejmoa2006923)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. <i>Internal Medicine Journal</i> , 2020, 50, 1483-1491.	0.5	19
3	Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 572-578.	0.7	2
4	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. <i>International Immunopharmacology</i> , 2020, 89, 107082.	1.7	23
5	The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 397-406.	0.8	16
6	Cardiovascular disease and cardiovascular outcomes in COVID-19. <i>Practical Diabetes</i> , 2020, 37, 191.	0.1	7
7	Coronavirus and Cardiometabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2024-2035.	1.2	38
8	Coronavirus disease 2019 (COVID-19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease. <i>European Eating Disorders Review</i> , 2020, 28, 799-815.	2.3	22
9	The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. <i>Biochimie</i> , 2020, 179, 85-100.	1.3	172
10	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1313-1324.	1.4	69
11	Acute Kidney Injury in COVID-19: The Chinese Experience. <i>Seminars in Nephrology</i> , 2020, 40, 430-442.	0.6	27
12	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 <sup>5</sup> -131 US Veterans With SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2020, 3, e2022310.	2.8	305
13	SARS-CoV-2-Related Kidney Injury: Current Concern and Challenges. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2015-2024.	0.3	5
14	Viral replication of SARS-CoV-2 could be self-limitative – The role of the renin-angiotensin system on COVID-19 pathophysiology. <i>Medical Hypotheses</i> , 2020, 145, 110330.	0.8	6
15	COVID-19's Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 3169-3192.	1.1	8
16	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1787-1795.	0.9	12
17	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00666.	1.1	18
18	The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. <i>Drugs and Aging</i> , 2020, 37, 779-785.	1.3	9
19	Strategies and Advances in Combating COVID-19 in China. <i>Engineering</i> , 2020, 6, 1076-1084.	3.2	16

#	ARTICLE	IF	CITATIONS
20	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 – A PHARMACOLOGICAL REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 2020, , 42-50.	0.3	2
22	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). Frontiers in Cardiovascular Medicine, 2020, 7, 585866.	1.1	63
23	Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. Journal of the American College of Cardiology, 2020, 76, 2011-2023.	1.2	165
24	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis, 2020, 313, 126-136.	0.4	52
25	Novel coronavirus disease in patients with end-stage kidney disease. Therapeutic Apheresis and Dialysis, 2020, 25, 544-550.	0.4	9
26	SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. Kidney International, 2020, 98, 1502-1518.	2.6	64
27	Statin use is associated with lower disease severity in COVID-19 infection. Scientific Reports, 2020, 10, 17458.	1.6	93
28	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. Journal of Fungi (Basel, Switzerland), 2020, 6, 211.	1.5	170
29	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). European Journal of Cancer, 2020, 140, 86-104.	1.3	33
30	Glucocorticoid excess and COVID-19 disease. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 703-714.	2.6	36
31	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Current Atherosclerosis Reports, 2020, 22, 72.	2.0	14
33	Do free radical NETWORK and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity?. Redox Biology, 2020, 37, 101721.	3.9	19
34	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology, 2020, 17, 543-558.	6.1	999
35	The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19. Obesity, 2020, 28, 2035-2035.	1.5	1
36	Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 2020, 80, 1267-1292.	4.9	208
37	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. European Journal of Clinical Pharmacology, 2020, 76, 1623-1630.	0.8	81
38	Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease. European Heart Journal, 2020, 41, 3097-3098.	1.0	4
39	Metabolic Syndrome and Viral Pathogenesis: Lessons from Influenza and Coronaviruses. Journal of Virology, 2020, 94, .	1.5	40

#	ARTICLE	IF	CITATIONS
40	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 1472.	2.2	38
41	Collateral damage: Fear from SARS-CoV2-infection causing Takotsubo cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2020, 109, 1588-1594.	1.5	4
42	Impact of COVID-19 Pandemic on Laboratory Utilization. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 1194-1205.	0.6	36
43	Will children reveal their secret? The coronavirus dilemma. <i>European Respiratory Journal</i> , 2020, 55, 2001617.	3.1	70
44	Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. <i>BMC Medicine</i> , 2020, 18, 220.	2.3	78
45	Comment on: COVID-19 and Older Adults: What We Know. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2197-2197.	1.3	2
46	Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?. <i>European Journal of Pharmacology</i> , 2020, 883, 173373.	1.7	34
48	COVID-19 in people with diabetes: understanding the reasons for worse outcomes. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 782-792.	5.5	668
49	Focus on Characteristics of COVID-19 with the Special Reference to the Impact of COVID-19 on the Urogenital System. <i>Current Urology</i> , 2020, 14, 79-84.	0.4	5
50	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. <i>Hypertension</i> , 2020, 76, 742-749.	1.3	33
52	Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. <i>Reviews in Medical Virology</i> , 2021, 31, e2194.	3.9	20
53	Outpatient Management of Oligosymptomatic Patients with respiratory infection in the era of SARS-CoV-2: Experience from rural German general practitioners. <i>BMC Infectious Diseases</i> , 2020, 20, 811.	1.3	5
54	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 593061.	1.1	3
55	Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity. <i>Frontiers in Physiology</i> , 2020, 11, 599729.	1.3	9
56	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8141.	1.8	4
57	COVID-19 and inhibitors of the renin-angiotensin-aldosterone system. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 815-816.	2.0	3
58	Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review. <i>Porto Biomedical Journal</i> , 2020, 5, e085.	0.4	12
59	Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 473-481.	0.1	9

#	ARTICLE	IF	CITATIONS
61	COVID-19 and cardiovascular diseases. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 161-167.	1.5	17
62	Possible Correlations between Atherosclerosis, Acute Coronary Syndromes and COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3746.	1.0	23
63	COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. <i>Cardiovascular Research</i> , 2020, 116, e198-e199.	1.8	13
64	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812097071.	0.6	5
65	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa519.	0.4	7
67	Coagulopatía en la infección por el virus SARS-CoV-2 (COVID-19): de los mecanismos fisiopatológicos al diagnóstico y tratamiento. <i>Acta Colombiana De Cuidado Intensivo</i> , 2022, 22, 44-54.	0.1	3
68	Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. <i>Annals of Internal Medicine</i> , 2020, 173, 195-203.	2.0	113
69	Professor Giuseppe Mancia receives the Excellence Research Award of the Council on Hypertension of the American Heart Association. <i>Blood Pressure</i> , 2020, 29, 338-338.	0.7	0
70	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. <i>Viruses</i> , 2020, 12, 1367.	1.5	15
71	A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW). <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 14402-14408.	2.4	13
72	Renin-angiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans. <i>Journal of Hypertension</i> , 2020, 38, 2384-2386.	0.3	1
73	SARS-CoV-2 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells. <i>Scientific Reports</i> , 2020, 10, 19522.	1.6	39
75	Conclusiones. COVID-19, del juicio clínico a la evidencia científica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 40-42.	0.2	0
76	Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. <i>Internal Medicine Journal</i> , 2020, 50, 1468-1474.	0.5	15
77	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2020, , .	0.7	58
78	The COVID-19 pandemic: A community approach. <i>Clinical Transplantation</i> , 2020, 34, e14059.	0.8	10
79	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020, 58, 102907.	2.7	110
80	Preadmission Diabetes-Specific Risk Factors for Mortality in Hospitalized Patients With Diabetes and Coronavirus Disease 2019. <i>Diabetes Care</i> , 2020, 43, 2339-2344.	4.3	81

#	ARTICLE	IF	CITATIONS
81	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. <i>Antioxidants</i> , 2020, 9, 636.	2.2	39
82	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , 2020, 34, 764-767.	1.0	25
83	COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. <i>IJC Heart and Vasculature</i> , 2020, 29, 100589.	0.6	45
84	Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2020, 56, 112-115.	0.2	1
85	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. <i>Journal of Drug Targeting</i> , 2020, 28, 683-699.	2.1	26
86	COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Canadian Pharmacists Journal</i> , 2020, 153, 193-197.	0.4	2
87	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5224.	1.8	42
88	&lt;p&gt;COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients&lt;/p&gt;. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1231-1240.	1.3	25
89	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
90	¿Es la enfermedad pulmonar obstructiva crÃ³nica un factor protector en la infecciÃ³n por SARS-CoV-2? La importancia del tratamiento broncodilatador. <i>Revista ClÃ­nica Espanola</i> , 2020, 220, 526-529.	0.2	5
91	Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes. <i>European Heart Journal</i> , 2020, 41, 3099-3099.	1.0	8
92	Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. , 2020, 11, 1069.		28
93	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. <i>Hypertension Research</i> , 2020, 43, 1028-1046.	1.5	131
94	Cardiovascular disease and <sc>COVID</sc> â€19: Australian and New Zealand consensus statement. <i>Medical Journal of Australia</i> , 2020, 213, 182-187.	0.8	54
95	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. <i>International Journal of Cardiology</i> , 2020, 321, 150-154.	0.8	12
96	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. <i>Cardiovascular Research</i> , 2020, 116, 2177-2184.	1.8	331
97	Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. <i>Archives of Gerontology and Geriatrics</i> , 2020, 91, 104204.	1.4	41
98	Treatment impact on COVID-19 evolution in hemodialysis patients. <i>Kidney International</i> , 2020, 98, 1053-1054.	2.6	14

#	ARTICLE	IF	CITATIONS
99	Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?. <i>Journal of Hypertension</i> , 2020, 38, 1614-1616.	0.3	7
100	The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. <i>Life Sciences</i> , 2020, 257, 118142.	2.0	14
101	Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19. <i>Medicina Clínica</i> , 2020, 155, 473-481.	0.3	7
102	Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. <i>Annals of Medicine</i> , 2020, 52, 361-366.	1.5	19
103	COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation?. <i>Renal Failure</i> , 2020, 42, 710-725.	0.8	13
104	Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1379-1388.	1.0	35
105	Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors. <i>European Journal of Anaesthesiology</i> , 2020, 37, 739-742.	0.7	2
106	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. <i>Obesity Facts</i> , 2020, 13, 439-452.	1.6	49
107	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. <i>Journal of Clinical Medicine</i> , 2020, 9, 2542.	1.0	2
108	COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. <i>Immunity and Ageing</i> , 2020, 17, 22.	1.8	37
109	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. <i>Annals of Medicine and Surgery</i> , 2020, 57, 236-243.	0.5	36
110	Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3472.	1.0	6
111	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 878-888.	1.4	43
112	Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. <i>BMJ Open</i> , 2020, 10, e043651.	0.8	69
113	Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2020, 31, 100627.	0.6	29
114	The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. <i>BMC Nephrology</i> , 2020, 21, 449.	0.8	61
115	RAAS Inhibitors and Risk of Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1990-1994.	13.9	21
116	Emergency Department Management of COVID-19: An Evidence-Based Approach. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 32-44.	0.6	3

#	ARTICLE	IF	CITATIONS
117	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. <i>Cell Discovery</i> , 2020, 6, 77.	3.1	54
118	The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. <i>IJC Heart and Vasculature</i> , 2020, 31, 100660.	0.6	25
119	ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. <i>Nature Communications</i> , 2020, 11, 5453.	5.8	191
120	Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1629-1641.	1.8	44
121	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 797-810.	0.7	7
122	Survey of the current status of subclinical coronavirus disease 2019 (COVID-19). <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 1294-1300.	0.8	13
123	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. <i>Journal of NeuroVirology</i> , 2020, 26, 631-641.	1.0	38
124	Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Hypertension</i> , 2020, 76, 1563-1571.	1.3	36
125	Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 75.	1.2	221
126	Is Sex a Determinant of COVID-19 Infection? Truth or Myth?. <i>Current Hypertension Reports</i> , 2020, 22, 62.	1.5	18
127	African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. <i>Clinical Rheumatology</i> , 2021, 40, 3445-3454.	1.0	11
128	COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1984-1986.	1.0	1
129	Cardiovascular Changes in Patients With COVID-19 From Wuhan, China. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 150.	1.1	9
130	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. <i>Internal and Emergency Medicine</i> , 2020, 15, 1457-1465.	1.0	32
131	Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. <i>Pathogens</i> , 2020, 9, 759.	1.2	46
132	Predictors at Admission of Mechanical Ventilation and Death in an Observational Cohort of Adults Hospitalized With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e4141-e4151.	2.9	28
133	Artificial intelligence in COVID-19 drug repurposing. <i>The Lancet Digital Health</i> , 2020, 2, e667-e676.	5.9	349
134	Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. <i>American Journal of Cardiology</i> , 2020, 136, 149-155.	0.7	134



#	ARTICLE	IF	CITATIONS
135	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52
136	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2943.	1.0	17
137	CSANZ Position Statement on COVID-19 From the Paediatric and Congenital Council. <i>Heart Lung and Circulation</i> , 2020, 29, e217-e221.	0.2	4
138	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 143.	1.1	35
139	COVID-19 and renin-angiotensin system modulators: what do we know so far?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 743-748.	0.6	9
140	Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 123-124.	0.8	0
141	Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. <i>European Journal of Heart Failure</i> , 2020, 22, 2205-2215.	2.9	173
142	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. <i>Hypertension</i> , 2020, 76, 1339-1349.	1.3	147
143	What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?. <i>Hypertension</i> , 2020, 76, 665-669.	1.3	3
144	Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System. <i>Hypertension</i> , 2020, 76, e34-e36.	1.3	57
145	Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?. <i>Frontiers in Immunology</i> , 2020, 11, 2014.	2.2	48
146	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. <i>Drug Safety</i> , 2020, 43, 1297-1308.	1.4	48
147	Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007115.	0.9	6
148	Is diabetes mellitus a risk factor for Coronavirus Disease 19 (COVID-19)?. <i>Acta Diabetologica</i> , 2020, 57, 1275-1285.	1.2	50
149	Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. <i>Genes</i> , 2020, 11, 1044.	1.0	52
150	Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. <i>American Journal of Hypertension</i> , 2020, 33, 1102-1111.	1.0	37
151	Kidney injury associated with COVID-19. <i>Cmaj</i> , 2020, 192, E1065-E1065.	0.9	3
152	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , 2020, 22, 90.	1.5	35

#	ARTICLE	IF	CITATIONS
153	ACE polymorphisms and COVID-19-related mortality in Europe. <i>Journal of Molecular Medicine</i> , 2020, 98, 1505-1509.	1.7	32
154	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. <i>ESC Heart Failure</i> , 2020, 7, 3464-3472.	1.4	19
155	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 919-930.	0.6	25
156	Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003308.	3.9	76
157	Dendritic Cells and SARS-CoV-2 Infection: Still an Unclarified Connection. <i>Cells</i> , 2020, 9, 2046.	1.8	46
158	COVID-19 Usurps Host Regulatory Networks. <i>Frontiers in Pharmacology</i> , 2020, 11, 1278.	1.6	27
159	Mortality and Pre-Hospitalization Use of Renin-Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID-19). <i>Journal of the American Heart Association</i> , 2020, 9, e017736.	1.6	24
160	Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. <i>Hypertension Research</i> , 2020, 43, 1257-1266.	1.5	43
161	Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders. <i>Frontiers in Medicine</i> , 2020, 7, 515.	1.2	7
162	Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study. <i>Journal of Human Hypertension</i> , 2021, 35, 588-597.	1.0	16
163	Sacubitril/Valsartan: Potential Impact of ARNi - Beyond the Wall of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 616564.	1.1	4
164	Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. <i>Journal of International Medical Research</i> , 2020, 48, 030006052097915.	0.4	16
165	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 4021.	1.0	13
166	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097909.	1.0	5
167	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 177-189.	0.3	2
168	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 568720.	1.1	5
169	Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity. <i>Frontiers in Immunology</i> , 2020, 11, 586111.	2.2	26
170	Associations between COVID-19 Incidence Rates and the Exposure to PM2.5 and NO2: A Nationwide Observational Study in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9318.	1.2	32

#	ARTICLE	IF	CITATIONS
171	Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. <i>Kidney360</i> , 2020, 1, 801-809.	0.9	23
172	Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study. <i>Journal of Infection</i> , 2020, 81, 961-965.	1.7	26
173	Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2559-2561.	1.4	5
174	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104510.	1.0	9
175	The significance of hyperglycaemia and other comorbidities during the COVID-19 pandemic. <i>Practical Diabetes</i> , 2020, 37, 157-169.	0.1	0
176	Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096895.	0.6	4
177	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 488-490.	0.1	6
178	SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7904.	1.8	22
179	Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. <i>Open Heart</i> , 2020, 7, e001353.	0.9	35
180	The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment. <i>Journal of Human Hypertension</i> , 2020, 35, 828-836.	1.0	1
181	SARS-CoV-2 (COVID-19) and the Endocrine System. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa144.	0.1	40
182	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. <i>Frontiers in Pharmacology</i> , 2020, 11, 588654.	1.6	99
183	COVID-19 Awareness Among Dental Professionals in Indonesia. <i>Frontiers in Medicine</i> , 2020, 7, 589759.	1.2	11
184	COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1539-1545.	1.2	32
185	Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. <i>Lancet, The</i> , 2020, 395, 1671-1673.	6.3	43
186	ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020, 158, 104927.	3.1	143
187	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
188	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. <i>Internal and Emergency Medicine</i> , 2020, 15, 759-766.	1.0	118

#	ARTICLE	IF	CITATIONS
189	Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2"exploring RAS inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 569-570.	1.9	14
190	Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. <i>Journal of Infection</i> , 2020, 81, 276-281.	1.7	73
191	COVID-19. <i>Hypertension</i> , 2020, 76, 294-299.	1.3	64
192	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. <i>European Journal of Heart Failure</i> , 2020, 22, 967-974.	2.9	163
193	Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. <i>N Engl J Med</i> . DOI: 10.1056/NEJMoa2007621.. <i>New England Journal of Medicine</i> , 2020, 382, 2464-2464.	13.9	27
194	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. <i>Pharmacological Research</i> , 2020, 158, 104906.	3.1	72
195	COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. <i>European Journal of Heart Failure</i> , 2020, 22, 957-966.	2.9	208
196	COVID-19 in diabetic patients: Related risks and specifics of management. <i>Annales D'Endocrinologie</i> , 2020, 81, 101-109.	0.6	65
197	Is the kidney a target of SARS-CoV-2?. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1454-F1462.	1.3	159
198	Response to "COVID-19 and ACEI/ARB: Not Associated?" <i>American Journal of Hypertension</i> , 2020, 33, 789-790.	1.0	2
199	Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 98-105.	0.9	34
200	Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1068-1080.	0.8	141
202	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042.	4.6	493
203	Covid-19 and cardiovascular disease. <i>BMJ</i> , The, 2020, 369, m1997.	3.0	16
204	Evidence That Renin-Angiotensin System Inhibitors Should Not Be Discontinued Due to the COVID-19 Pandemic. <i>Hypertension</i> , 2020, 76, 42-43.	1.3	7
205	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
206	COVID-19: a brief history and treatments in development. <i>The Prescriber</i> , 2020, 31, 23-28.	0.1	35
207	COVID-19 "Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?". <i>Heart Lung and Circulation</i> , 2020, 29, 964-972.	0.2	25

#	ARTICLE	IF	CITATIONS
208	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. <i>Joint Bone Spine</i> , 2020, 87, 431-437.	0.8	20
209	COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?. <i>Journal of Internal Medicine</i> , 2020, 288, 410-421.	2.7	38
211	Association between renin-angiotensin system inhibitors and COVID-19 complications. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 426-434.	1.4	46
212	ACE2 and COVID-19 and the resulting ARDS. <i>Postgraduate Medical Journal</i> , 2020, 96, 403-407.	0.9	94
213	Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?. <i>Current Hypertension Reports</i> , 2020, 22, 43.	1.5	37
214	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	1.3	330
215	The Impact of the COVID-19 - Infodemic on Drug-Utilization Behaviors: Implications for Pharmacovigilance. <i>Drug Safety</i> , 2020, 43, 699-709.	1.4	56
216	Association between angiotensin blockade and COVID-19 severity in Hong Kong. <i>Cmaj</i> , 2020, 192, E635-E635.	0.9	7
217	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	7.2	400
218	Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling. <i>Frontiers in Pharmacology</i> , 2020, 11, 836.	1.6	47
219	COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1053-1060.	1.8	36
220	COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. <i>Heart</i> , 2020, 106, 1127-1131.	1.2	172
221	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 159-161.	0.7	23
222	Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?. <i>Pharmacological Research</i> , 2020, 159, 104959.	3.1	4
223	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 412-414.	1.4	51
224	Potential role of statins in COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 96, 615-617.	1.5	85
225	Heart failure in the course of a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 1755-1758.	2.9	5
227	Cardiovascular disease and the impact of COVID-19. <i>Journal of Cardiac Surgery</i> , 2020, 35, 2113-2113.	0.3	8

#	ARTICLE	IF	CITATIONS
228	Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 168.	3.8	331
229	Clinical Characteristics and Outcomes of Community- and Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System. <i>CardioRenal Medicine</i> , 2020, 10, 223-231.	0.7	65
230	Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1227-1235.	1.1	29
231	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 682-689.	1.6	221
232	COVID-19: from epidemiology to treatment. <i>European Heart Journal</i> , 2020, 41, 2092-2112.	1.0	67
233	Renin-angiotensin system inhibition in COVID-19 patients. <i>Netherlands Heart Journal</i> , 2020, 28, 396-405.	0.3	15
234	Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. <i>American Journal of Hypertension</i> , 2020, 33, 944-948.	1.0	72
235	Acute kidney injury in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 1339-1348.	3.9	385
236	Does Ibuprofen Worsen COVID-19?. <i>Drug Safety</i> , 2020, 43, 611-614.	1.4	66
237	Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. <i>Journal of the American College of Cardiology</i> , 2020, 76, 533-546.	1.2	592
238	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
239	COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. <i>American Heart Journal</i> , 2020, 226, 174-187.	1.2	15
240	The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?. <i>Acta Clinica Belgica</i> , 2020, , 1-8.	0.5	10
241	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. <i>Medicina Clínica</i> , 2020, 155, 488-490.	0.3	13
242	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e4197-e4205.	2.9	337
243	Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. <i>Endocrinology</i> , 2020, 161, .	1.4	80
244	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 2030.	1.0	28
245	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. <i>Heart</i> , 2020, 106, 1519-1524.	1.2	83

#	ARTICLE	IF	CITATIONS
247	Renin-Angiotensin System Blockade in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 277-279.	1.2	7
248	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L325-L336.	1.3	69
249	Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. , 2020, 215, 107628.		41
250	COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1109-1119.	1.0	45
251	Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 782.	3.8	3,597
253	COVID-19 and the Renin Angiotensin System: Implications for the Older Adults. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 699-704.	1.5	21
256	In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1553-1556.	1.4	3
257	COVID-19: From pathogenesis models to the first drug trials. <i>Microbial Biotechnology</i> , 2020, 13, 1289-1299.	2.0	2
258	Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. <i>PLoS ONE</i> , 2020, 15, e0235248.	1.1	71
259	Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes Involved in SARS-CoV-2 Infection and Human Quantitative Phenotypes. <i>Frontiers in Genetics</i> , 2020, 11, 613.	1.1	45
260	SARS-CoV-2 pandemic: An overview. <i>Advances in Biological Regulation</i> , 2020, 77, 100736.	1.4	65
261	Susceptibility and prognosis of COVID-19 patients with cardiovascular disease. <i>Open Heart</i> , 2020, 7, e001310.	0.9	8
262	Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19. <i>Cmaj</i> , 2020, 192, E611-E611.	0.9	1
263	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
264	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. <i>Frontiers of Medicine</i> , 2020, 14, 601-612.	1.5	38
265	COVID-19 and diabetes: What does the clinician need to know?. <i>Primary Care Diabetes</i> , 2020, 14, 558-563.	0.9	38
266	Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 404-411.	0.6	13
267	COVID-19 and arterial hypertension: Hypothesis or evidence?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1120-1126.	1.0	65

#	ARTICLE	IF	CITATIONS
268	Molecular Aspects of COVID-19 Differential Pathogenesis. <i>Pathogens</i> , 2020, 9, 538.	1.2	18
269	Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2462-2464.	13.9	107
270	Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1757-1766.	13.9	1,087
272	A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 148-157.	1.4	72
273	COVID-19 pandemic: a time for collaboration and a unified global health front. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	0.9	16
274	Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 76-77.	1.4	19
275	ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?. <i>American Journal of Hypertension</i> , 2021, 34, 274-277.	1.0	9
276	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. <i>Journal of Cardiology</i> , 2021, 77, 482-491.	0.8	49
277	The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e48-e51.	1.4	61
278	Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 843-850.	1.8	41
279	Covid-19 and the cardiovascular system: a comprehensive review. <i>Journal of Human Hypertension</i> , 2021, 35, 4-11.	1.0	238
280	What Now? Epidemiology in the Wake of a Pandemic. <i>American Journal of Epidemiology</i> , 2021, 190, 17-20.	1.6	13
281	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 249-259.	1.3	33
282	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. <i>Inflammation</i> , 2021, 44, 13-34.	1.7	162
283	Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 2084-2089.	2.5	17
284	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. , 2021, 219, 107703.		50
285	The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 72, e901-e913.	2.9	35
286	COVID-19 - A vascular disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 1-5.	2.3	254



#	ARTICLE	IF	CITATIONS
287	Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019. <i>Cardiovascular Research</i> , 2021, 117, 85-95.	1.8	15
288	Cardiac Involvement of COVID-19: A Comprehensive Review. <i>American Journal of the Medical Sciences</i> , 2021, 361, 14-22.	0.4	104
289	The role of inflammation in hypertension: novel concepts. <i>Current Opinion in Physiology</i> , 2021, 19, 92-98.	0.9	57
290	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1-12.	5.7	93
291	Renin-angiotensin-aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study. <i>American Journal of Hypertension</i> , 2021, 34, 339-347.	1.0	27
292	Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 396-398.	1.1	36
293	Using genetics to understand the role of antihypertensive drugs modulating angiotensin-converting enzyme in immune function and inflammation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1839-1846.	1.1	5
294	Direct oral anticoagulant use and risk of severe COVID-19. <i>Journal of Internal Medicine</i> , 2021, 289, 411-419.	2.7	76
295	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. , 2021, 221, 107750.		34
296	The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104647.	1.0	60
297	Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. <i>Archives of Disease in Childhood</i> , 2021, 106, 429-439.	1.0	374
298	Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 476-485.	2.9	46
299	Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 21-27.	1.0	31
300	Insights into heart failure hospitalizations, management, and services during and beyond COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 175-182.	1.4	22
301	Coronavirus Disease 2019-associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. <i>Journal of the American Heart Association</i> , 2021, 10, e019650.	1.6	122
302	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L301-L330.	1.3	26
304	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 49-64.	10.6	126
305	Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. <i>Acta Cardiologica</i> , 2021, 76, 109-124.	0.3	42

#	ARTICLE	IF	CITATIONS
306	Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2475-2492.	1.1	27
307	Insights into disparities observed with COVID-19. <i>Journal of Internal Medicine</i> , 2021, 289, 463-473.	2.7	92
308	Characterising and managing paediatric SARS-CoV-2 infection: Learning about the virus in a global classroom. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 409-422.	0.7	2
309	How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. <i>European Journal of Internal Medicine</i> , 2021, 83, 1-5.	1.0	35
310	Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 693-701.	2.0	108
311	A data-driven approach to identify risk profiles and protective drugs in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	32
312	The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 190-195.	0.3	22
313	Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 192-193.	1.0	2
315	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System. <i>Journal of the American Heart Association</i> , 2021, 10, e019669.	1.6	26
316	Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. <i>The Lancet Digital Health</i> , 2021, 3, e98-e114.	5.9	94
317	Conflicts over calcium and the treatment of COVID-19. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 149-156.	1.1	49
318	SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. <i>Thorax</i> , 2021, 76, 370-379.	2.7	15
319	The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2021, 50, 75-86.	0.9	10
320	Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). <i>American Journal of the Medical Sciences</i> , 2021, 361, 287-296.	0.4	20
321	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 87-94.	0.4	259
322	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	129
323	Cardiac arrest and COVID-19: inflammation, angiotensin-converting enzyme 2, and the destabilization of non-significant coronary artery disease—a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa475.	0.3	0
324	Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. <i>Nutrition</i> , 2021, 81, 111016.	1.1	89

#	ARTICLE	IF	CITATIONS
325	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 194-203.	1.0	17
326	Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. <i>Annals of Pharmacotherapy</i> , 2021, 55, 805-813.	0.9	1
327	Translating bioactive peptides for COVID-19 therapy. <i>European Journal of Pharmacology</i> , 2021, 890, 173661.	1.7	15
328	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 183-202.	1.4	62
329	The pivotal role of the angiotensin-II- $\text{NF-}\kappa\text{B}$ axis in the development of COVID-19 pathophysiology. <i>Hypertension Research</i> , 2021, 44, 126-128.	1.5	18
330	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. <i>Angiology</i> , 2021, 72, 122-130.	0.8	20
331	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
332	Cardiovascular considerations for anesthesiologists during the COVID-19 pandemic. <i>Journal of Anesthesia</i> , 2021, 35, 361-365.	0.7	3
333	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. <i>CJC Open</i> , 2021, 3, 28-40.	0.7	7
334	COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 345-357.	2.0	157
335	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. <i>Canadian Journal of Diabetes</i> , 2021, 45, 162-166.e1.	0.4	19
336	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. <i>Immunology and Cell Biology</i> , 2021, 99, 192-205.	1.0	5
337	History and Recent Advances in Coronavirus Discovery. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 3-24.	0.1	3
338	The renin-angiotensin system in pediatric kidney disease: from pathophysiology to the novel therapeutic approach. <i>Japanese Journal of Pediatric Nephrology</i> , 2021, 34, 7-12.	0.0	0
339	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. <i>Heart Failure Reviews</i> , 2021, 26, 961-971.	1.7	10
340	Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. <i>World Journal of Clinical Cases</i> , 2021, 9, 47-60.	0.3	3
341	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>European Heart Journal</i> , 2021, 42, 657-670.	1.0	25
342	Current treatment in COVID-19 disease: a rapid review. <i>Drugs in Context</i> , 2021, 10, 1-8.	1.0	51

#	ARTICLE	IF	CITATIONS
343	The interactive effects of ambient air pollutants-meteorological factors on confirmed cases of COVID-19 in 120 Chinese cities. <i>Environmental Science and Pollution Research</i> , 2021, 28, 27056-27066.	2.7	13
344	Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 943-951.	0.5	66
345	COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. <i>Current Hypertension Reviews</i> , 2021, 17, .	0.5	2
346	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 905-919.	1.3	445
347	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 254.	3.8	299
348	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
349	COVID-19 and Cerebrovascular Diseases. , 2021, , 57-72.		0
350	Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 176-192.	1.7	40
351	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
352	Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19). <i>Southern Medical Journal</i> , 2021, 114, 51-56.	0.3	14
353	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 231-247.	1.3	22
354	COVID-19 in Patients with Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 243-261.	0.8	3
355	COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. <i>Journal of Human Hypertension</i> , 2021, 35, 304-307.	1.0	60
356	Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 13-56.	1.6	33
357	Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0246182.	1.1	7
358	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 5-11.	1.0	21
359	Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. <i>Clinics</i> , 2021, 76, e2342.	0.6	8
360	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 "care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111

#	ARTICLE	IF	CITATIONS
361	Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. <i>Clinical Research in Cardiology</i> , 2021, 110, 1041-1050.	1.5	49
362	The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098819.	1.4	3
363	Ecological Analysis of the Influence of ACEIs and ARBs on the COVID-19 Prevalence and Death from COVID-19. <i>Health</i> , 2021, 13, 619-628.	0.1	1
364	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. <i>Clinical Science</i> , 2021, 135, 1-17.	1.8	17
365	Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. <i>Thorax</i> , 2021, 76, 479-486.	2.7	16
366	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e045482.	0.8	35
367	No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COVID MEDication (COMET) study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3301-3309.	1.1	6
368	An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 630209.	1.2	16
369	The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. <i>Acta Diabetologica</i> , 2021, 58, 831-843.	1.2	46
370	Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19: A Meta-Analysis and Systematic Review. <i>Cureus</i> , 2021, 13, e13124.	0.2	4
371	Association between COVID-19 and Cardiovascular disease. <i>Journal of the Nihon University Medical Association</i> , 2021, 80, 3-5.	0.0	0
372	To Curb the Progression of Fatal COVID-19 Course – Dream or Reality. <i>Current Hypertension Reports</i> , 2021, 23, 12.	1.5	3
373	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
374	Renin-angiotensin system blockade in the COVID-19 pandemic. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i48-i59.	1.4	17
375	Renin-angiotensin system inhibitors and COVID-19: overwhelming evidence against an association. <i>The Lancet Digital Health</i> , 2021, 3, e70-e71.	5.9	2
376	Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. <i>Current Opinion in Anaesthesiology</i> , 2021, 34, 187-198.	0.9	1
377	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. <i>Frontiers in Physiology</i> , 2021, 12, 624052.	1.3	12
378	Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. <i>Clinical Science</i> , 2021, 135, 465-481.	1.8	45

#	ARTICLE	IF	CITATIONS
379	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. <i>European Heart Journal</i> , 2021, 42, 1061-1062.	1.0	2
380	Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 201.	0.4	0
382	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
383	COVID-19-associated liver injury: from bedside to bench. <i>Journal of Gastroenterology</i> , 2021, 56, 218-230.	2.3	39
384	Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021, 49, e613-e623.	0.4	23
385	Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e25452.	1.2	14
386	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 82-93.	5.5	251
389	Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19). <i>Cureus</i> , 2021, 13, e13429.	0.2	2
390	Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation. <i>BMJ Open</i> , 2021, 11, e044486.	0.8	24
391	Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. <i>BMJ Open</i> , 2021, 11, e043625.	0.8	11
392	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 51.	2.3	41
393	Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. <i>Annals of Internal Medicine</i> , 2021, 174, W25-W29.	2.0	9
395	Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. <i>Journal of Hypertension</i> , 2021, 39, 784-794.	0.3	34
397	A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. <i>FASEB Journal</i> , 2021, 35, e21419.	0.2	4
398	The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. <i>PLoS ONE</i> , 2021, 16, e0246190.	1.1	64
399	Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2021, 74, 1740-1751.	0.6	16
400	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 772-810.	1.2	612
401	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. <i>Journal of Hypertension</i> , 2021, 39, 1282-1292.	0.3	62

#	ARTICLE	IF	CITATIONS
402	Neurological symptoms of COVID-19. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2021, 36, 285-296.	0.1	0
403	Hypertension artérielle et COVID-19. <i>La Presse Médicale Formation</i> , 2021, 2, 25-32.	0.1	2
404	Cardiac point-of-care ultrasound in hospitalized coronavirus disease-2019 patients. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, e3-e7.	0.6	3
405	Hypertension and COVID-19: Ongoing Controversies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 639222.	1.1	38
406	Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2. <i>ESC Heart Failure</i> , 2021, 8, 1717-1721.	1.4	8
407	Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?. <i>Hypertension</i> , 2021, 77, 843-845.	1.3	1
408	Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts. <i>PLoS ONE</i> , 2021, 16, e0247548.	1.1	8
409	An Overview of Drugs Used in COVID-19: A Pharmacotherapeutic Approach. <i>International Journal of Health Sciences and Pharmacy</i> , 0, , 34-54.	0.0	0
410	Problem issues of the pathogenesis of inflammatory reaction and the course of coronavirus infection. <i>Tuberculosis Lung Diseases HIV Infection</i> , 2021, , 76-86.	0.3	0
413	Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. <i>Journal of Clinical Medicine</i> , 2021, 10, 1073.	1.0	6
414	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. <i>Health Care Management Science</i> , 2021, 24, 339-355.	1.5	8
415	COVID-19 and its impact on the cardiovascular system. <i>Open Heart</i> , 2021, 8, e001472.	0.9	27
416	Hypertension in Patients Hospitalized with COVID-19 in Wuhan, China. <i>International Heart Journal</i> , 2021, 62, 337-343.	0.5	4
417	COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1083-1092.	2.0	13
418	Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care. <i>BMC Infectious Diseases</i> , 2021, 21, 262.	1.3	8
419	Outcomes of COVID-19-positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. <i>Journal of Internal Medicine</i> , 2021, 290, 88-100.	2.7	43
420	Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors. <i>IScience</i> , 2021, 24, 102188.	1.9	13
421	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <i>International Journal of Infectious Diseases</i> , 2021, 104, 7-14.	1.5	13

#	ARTICLE	IF	CITATIONS
422	Antihypertensive Drugs and COVID-19 Risk. <i>Hypertension</i> , 2021, 77, 833-842.	1.3	94
423	Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis. <i>Scientific Reports</i> , 2021, 11, 5012.	1.6	18
424	Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 144-157.	1.5	49
425	SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. <i>PLoS ONE</i> , 2021, 16, e0248498.	1.1	30
426	Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 73.	1.1	8
427	Anticoagulación en COVID-19, ¿qué sabemos hoy y qué falta definirse?: una revisión crítica del Comité Vasculares de Neumología. <i>Revista Colombiana De Neumología</i> , 2021, 32, 98-114.	0.1	0
428	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 255-262.	1.0	1
429	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e213594.	2.8	92
430	The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. <i>Current Hypertension Reports</i> , 2021, 23, 17.	1.5	6
432	Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S114-S122.	0.7	11
433	The Renin-Angiotensin-Aldosterone System and Coronavirus Disease 2019. <i>European Cardiology Review</i> , 2021, 16, e07.	0.7	26
434	Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. <i>European Journal of Epidemiology</i> , 2021, 36, 287-298.	2.5	102
435	Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. <i>Hypertension Research</i> , 2021, 44, 955-968.	1.5	15
436	Severe Acute Respiratory Syndrome-Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research. , 2021, 3, e0374.		20
437	Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 275-284.	5.2	198
439	ACEI/ARB drug therapy in COVID-19 patients: Yes or no?. <i>Journal of Translational Internal Medicine</i> , 2021, 9, 8-11.	1.0	2
440	Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S123-S131.	0.7	12
441	Renin-angiotensin system inhibitors in hospitalised patients with COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 221-222.	5.2	7



#	ARTICLE	IF	CITATIONS
442	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
443	Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 620990.	1.2	26
444	Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system. <i>Meditinskiy Sovet</i> , 2021, , 59-67.	0.1	0
445	The effect of renin-angiotensin-aldosterone blockers on SARS-CoV-2 infection in adults: a systematic review of studies and meta-analyses. <i>Meditinskiy Sovet</i> , 2021, , 26-33.	0.1	0
446	Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. <i>Journal of Hypertension</i> , 2021, 39, 1717-1724.	0.3	22
447	Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19. <i>European Heart Journal</i> , 2021, 42, 1720-1721.	1.0	8
448	Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4526.	1.8	48
449	Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. <i>Infection</i> , 2021, 49, 725-737.	2.3	14
450	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	1.0	37
451	Hypertension, a Moving Target in COVID-19. <i>Circulation Research</i> , 2021, 128, 1062-1079.	2.0	61
452	Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. <i>Open Heart</i> , 2021, 8, e001526.	0.9	22
453	Drugs acting on the renin-angiotensin system and SARS-CoV-2. <i>Drug Discovery Today</i> , 2021, 26, 870-874.	3.2	33
454	Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. <i>Advances in Therapy</i> , 2021, 38, 2709-2716.	1.3	2
455	Does taking an angiotensin inhibitor increase the risk for COVID-19? â€” a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 10853-10865.	1.4	7
456	The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 667254.	1.6	39
458	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.0	4
459	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>Cardiologia Croatica</i> , 2021, 16, 140-156.	0.0	0
460	Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. <i>Cardiovascular Research</i> , 2021, 117, 1823-1840.	1.8	17

#	ARTICLE	IF	CITATIONS
461	The fight against COVID-19: Striking a balance in the renin-angiotensin system. <i>Drug Discovery Today</i> , 2021, 26, 2214-2220.	3.2	11
462	The aging lung: Physiology, disease, and immunity. <i>Cell</i> , 2021, 184, 1990-2019.	13.5	175
463	RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. <i>Contemporary Clinical Trials</i> , 2021, 103, 106330.	0.8	9
464	The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 987-1000.	1.0	11
465	Expression of the SARS-CoV-2 receptor ACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin-angiotensin system. <i>Cardiovascular Diabetology</i> , 2021, 20, 90.	2.7	30
466	Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 330-340.	1.3	5
467	Drug-utilisation profiles and COVID-19. <i>Scientific Reports</i> , 2021, 11, 8913.	1.6	12
468	Clinical characteristics and outcomes of COVID-19 patients with diabetes mellitus in Kuwait. <i>Heliyon</i> , 2021, 7, e06706.	1.4	18
469	Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab170.	0.4	2
470	Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 609857.	1.1	11
471	COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. <i>Nature Communications</i> , 2021, 12, 2417.	5.8	75
472	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. <i>Eurasian Journal of Medicine</i> , 2021, 53, 137-143.	0.2	5
473	Case of severe liver damage in COVID-19. <i>Meditinskiy Sovet</i> , 2021, , 84-91.	0.1	3
474	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2025609118.	3.3	1
475	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. <i>Biomolecules</i> , 2021, 11, 787.	1.8	14
478	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1323-1330.	1.8	26
479	Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100105.	3.0	77
480	Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the United Kingdom. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4598-4607.	1.1	18

#	ARTICLE	IF	CITATIONS
481	Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 617-628.	0.7	3
482	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4421-4431.	1.1	39
483	Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 577398.	1.1	3
484	Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. <i>Nature Reviews Cardiology</i> , 2021, 18, 785-802.	6.1	515
485	Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 430-438.	1.8	4
486	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
487	Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies. <i>Pathogens</i> , 2021, 10, 582.	1.2	17
488	Harmful Effects of COVID-19 on Major Human Body Organs: A Review. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 500-511.	0.3	6
489	Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e102-e109.	1.7	22
490	Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. <i>BMC Medicine</i> , 2021, 19, 118.	2.3	14
491	Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19. <i>Clinical Hypertension</i> , 2021, 27, 11.	0.7	3
492	Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 405-416.	1.0	7
493	Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 13588.	1.6	8
494	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity. <i>Scientific Reports</i> , 2021, 11, 13349.	1.6	4
495	Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data. <i>Cancer Letters</i> , 2021, 508, 30-46.	3.2	14
496	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272.	0.7	18
497	Antihypertensives and COVID-19: Literature review. <i>Research, Society and Development</i> , 2021, 10, e41510615977.	0.0	0
498	Covid and Cardiovascular Diseases: Direct and Indirect Damages and Future Perspective. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 439-445.	1.0	25

#	ARTICLE	IF	CITATIONS
499	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2642.	1.0	9
500	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1061-1072.	2.2	7
501	Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. <i>JAMA Network Open</i> , 2021, 4, e2113186.	2.8	43
502	Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. <i>BMC Infectious Diseases</i> , 2021, 21, 527.	1.3	9
503	Practical considerations for cardiovascular care during COVID-19 pandemic. <i>International Journal of Advances in Medicine</i> , 2021, 8, 994.	0.0	0
504	COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. <i>Frontiers in Endocrinology</i> , 2021, 12, 649525.	1.5	124
505	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111469.	2.5	3
506	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e46-e59.	2.9	9
507	Day-by-day blood pressure variability in hospitalized patients with COVID-19. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1675-1680.	1.0	11
508	Expression of SARS-CoV-2 receptor ACE2 in human pancreatic Î² cells: to be or not to be!. <i>Islets</i> , 2021, 13, 106-114.	0.9	12
509	Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension. <i>Frontiers of Medicine</i> , 2022, 16, 102-110.	1.5	10
510	Current Understanding of Clinical Manifestations of COVID-19 in Glomerular Disease. <i>Glomerular Diseases</i> , 2021, 1, 250-264.	0.2	6
511	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40
512	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> , 2021, 37, 100957.	3.2	56
513	The Value of Medical Registries and Observational Studies Early in Pandemics: The Coronavirus Disease 2019 (COVID-19) Experience. <i>Clinical Infectious Diseases</i> , 2022, 74, 1112-1116.	2.9	5
514	Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients. <i>Annals of Translational Medicine</i> , 2021, 9, 1054-1054.	0.7	4
515	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? – The Summarising Review. <i>International Journal of Public Health</i> , 2021, 66, 1603975.	1.0	3
516	Arterial hypertension. <i>Lancet</i> , The, 2021, 398, 249-261.	6.3	100

#	ARTICLE	IF	CITATIONS
517	Predictors of COVID-19 in an outpatient fever clinic. PLoS ONE, 2021, 16, e0254990.	1.1	6
519	Bacille Calmette-Guérin: An Ophthalmic perspective. Survey of Ophthalmology, 2021, , .	1.7	2
520	Role of Hypertension on the Severity of COVID-19: A Review. Journal of Cardiovascular Pharmacology, 2021, 78, e648-e655.	0.8	64
521	Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 151-170.	2.6	20
522	Cardiovascular system in the sars-CoV-2: impact of therapies. Journal of Hypertension, 2021, 39, 1306-1308.	0.3	1
523	Insulin Therapy and Outcome of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 481-489.	0.6	8
525	Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for) Tj ETQq0 0 0 rgBT /Overlock 100f 50 497		
526	Risk factors for COVID-19 hospitalisation and death in people living with diabetes: A virtual cohort study from the Western Cape Province, South Africa. Diabetes Research and Clinical Practice, 2021, 177, 108925.	1.1	12
527	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19. Journal of the American Heart Association, 2021, 10, e018086.	1.6	45
528	NSAIDs and COVID-19: A Systematic Review and Meta-analysis. Drug Safety, 2021, 44, 929-938.	1.4	53
529	Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. Journal of the American Heart Association, 2021, 10, e021154.	1.6	10
530	COVID-19 and the impact of arterial hypertension” An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). European Journal of Clinical Investigation, 2021, 51, e13582.	1.7	14
531	Pronóstico de los pacientes hospitalizados por Covid-19 que utilizaban inhibidores de la enzima convertidora de angiotensina o antagonistas del receptor de angiotensina II. Repertorio De Medicina Y Cirugia, 0, , .	0.0	0
532	Role of Potential COVID-19 Immune System Associated Genes and the Potential Pathways Linkage with Type-2 Diabetes. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2452-2462.	0.6	11
533	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respiratory Medicine,the, 2021, 9, 863-872.	5.2	75
534	COVID-19: a 21st century cataclysmic pandemic. Sleep Medicine, 2022, 91, 151-153.	0.8	2
535	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Advances in Biological Regulation, 2021, 81, 100818.	1.4	10
536	Is diabetes mellitus a wrongdoer to COVID-19 severity?. Diabetes Research and Clinical Practice, 2021, 178, 108936.	1.1	9

#	ARTICLE	IF	CITATIONS
537	Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology. <i>CJC Open</i> , 2021, 3, 1060-1074.	0.7	14
538	Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation. <i>ESC Heart Failure</i> , 2021, 8, 4119-4129.	1.4	7
539	Immune response to SARS-CoV-2 in children: A review of the current knowledge. <i>Pediatric Investigation</i> , 2021, 5, 217-228.	0.6	17
540	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 923-928.	0.2	5
541	Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. <i>Drugs and Aging</i> , 2021, 38, 921-930.	1.3	5
542	Updates on Renin-Angiotensin System Blockers in Hypertensive Patients With COVID-19. <i>American Journal of Hypertension</i> , 2021, , .	1.0	4
543	ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. <i>Acta Physiologica</i> , 2021, 233, e13733.	1.8	12
544	Cardiovascular system and coronavirus disease-2019 (COVID-19): mutual injuries and unexpected outcomes. <i>Egyptian Heart Journal</i> , 2021, 73, 77.	0.4	4
546	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	1.4	26
547	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A shaped alarming curve.. <i>Archives of Medical Science</i> , 2021, , .	0.4	4
548	Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	6
549	The Impact of Obesity on SARS-CoV-2 Pandemic Mortality Risk. <i>Nutrients</i> , 2021, 13, 3446.	1.7	5
550	Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-inflammatory Drugs: Systematic Review and Meta-Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1521-1533.	1.0	7
551	Arterial hypertension Clinical trials update 2021. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 21-31.	1.1	42
552	Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality. <i>Systematic Reviews</i> , 2021, 10, 243.	2.5	7
553	Clinical and laboratory factors associated with coronavirus disease 2019 (Covid-19): A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2021, 31, e2288.	3.9	13
554	Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin. <i>International Journal of Cardiology</i> , 2021, 338, 278-285.	0.8	18
555	Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. <i>Stem Cell Reports</i> , 2021, 16, 2459-2472.	2.3	11

#	ARTICLE	IF	CITATIONS
556	COVID-19 and chronic kidney disease: a comprehensive review. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 383-399.	0.4	32
557	The Crosstalk between SARS-CoV-2 Infection and the RAA System in Essential Hypertension—Analyses Using Systems Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10518.	1.8	3
558	Impact of COVID-19 on Heart Failure Patients in South Korea. <i>International Heart Journal</i> , 2021, 62, 1083-1090.	0.5	1
560	Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	3
561	Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium. <i>BMJ Open</i> , 2021, 11, e053393.	0.8	5
563	Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. <i>Journal of General Internal Medicine</i> , 2021, 36, 3802-3809.	1.3	2
564	Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system. <i>American Heart Journal</i> , 2021, 240, 46-57.	1.2	4
565	In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
566	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. <i>Pharmacological Research</i> , 2021, 173, 105848.	3.1	16
567	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
568	Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. <i>American Journal of Nephrology</i> , 2021, 52, 250-260.	1.4	14
569	COVID-19 and Vulnerable Populations in Sub-Saharan Africa. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 147-162.	0.8	2
570	The influence of pre-existing hypertension on coronavirus disease 2019 patients. <i>Epidemiology and Infection</i> , 2021, 149, e4.	1.0	14
571	Effects of Bariatric Surgery on COVID-19: a Multicentric Study from a High Incidence Area. <i>Obesity Surgery</i> , 2021, 31, 2477-2488.	1.1	19
572	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , 2022, 43, 1033-1058.	1.0	80
573	Renin Angiotensin System and Covid-19 Infection. <i>Advanced Pharmaceutical Bulletin</i> , 2021, 12, 1-4.	0.6	1
574	Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: A population-based cohort study from Italy. <i>PLoS ONE</i> , 2021, 16, e0237202.	1.1	18
575	Myocardial injury in COVID-19. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 303-306.	0.1	0

#	ARTICLE	IF	CITATIONS
576	Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy. <i>European Journal of Heart Failure</i> , 2021, 23, 486-488.	2.9	2
577	A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs. <i>Cureus</i> , 2021, 13, e12757.	0.2	1
578	Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 37-50.	1.1	17
579	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021, 50, 245-261.	0.8	32
580	Flow cytometric evaluation of the neutrophil compartment in COVID-19 at hospital presentation: A normal response to an abnormal situation. <i>Journal of Leukocyte Biology</i> , 2021, 109, 99-114.	1.5	19
581	First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)". <i>Infection</i> , 2021, 49, 63-73.	2.3	62
582	Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. <i>Diabetes and Metabolism</i> , 2020, 46, 265-271.	1.4	119
583	SARS-CoV-2 and diabetes: New challenges for the disease. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108228.	1.1	48
584	The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 31-33.	0.4	6
585	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	1.0	39
586	A historical perspective on ACE2 in the COVID-19 era. <i>Journal of Human Hypertension</i> , 2021, 35, 935-939.	1.0	41
587	RAAS inhibitors do not increase the risk of COVID-19. <i>Nature Reviews Cardiology</i> , 2020, 17, 383-383.	6.1	16
588	Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 418-426.	0.6	44
589	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. <i>Blood Pressure</i> , 2021, 30, 1-3.	0.7	16
590	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
591	Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence. <i>American Journal of Hypertension</i> , 2021, 34, 327-329.	1.0	2
592	Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2121-2128.	2.9	93
593	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 297-306.	1.4	59



#	ARTICLE	IF	CITATIONS
594	Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 124-131.	1.4	19
595	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. CKJ: Clinical Kidney Journal, 2020, 13, 913-925.	1.4	11
596	Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?. Journal of Cardiovascular Pharmacology, 2021, 77, 323-331.	0.8	20
597	Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. Journal of Hypertension, 2020, 38, 2537-2541.	0.3	20
598	Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. Journal of Hypertension, 2021, 39, 367-375.	0.3	17
599	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. Journal of Hypertension, 2021, 39, 376-380.	0.3	20
600	Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding. Journal of Hypertension, 2021, 39, 795-805.	0.3	41
601	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	5
628	The influence of diabetes and hypertension on outcome in COVID-19 patients: Do we mix apples and oranges?. Journal of Clinical Hypertension, 2021, 23, 235-237.	1.0	13
629	Manipulation of ACE2 expression in COVID-19. Open Heart, 2020, 7, e001424.	0.9	55
630	COVID-19 and the heart: what we have learnt so far. Postgraduate Medical Journal, 2021, 97, 655-666.	0.9	10
631	Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. Annals of Intensive Care, 2020, 10, 73.	2.2	151
632	A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Medical Science Monitor, 2020, 26, e926651.	0.5	16
633	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS ONE, 2020, 15, e0244131.	1.1	46
634	Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia. PLoS ONE, 2020, 15, e0244349.	1.1	7
635	Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study. PLoS ONE, 2020, 15, e0244708.	1.1	7
636	Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. Anatolian Journal of Cardiology, 2020, 24, 21-29.	0.5	36
637	Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Journal of Endocrinology, 2020, 247, R45-R62.	1.2	43

#	ARTICLE	IF	CITATIONS
638	The Coronavirus Disease 2019 Outbreak Highlights the Importance of Sex-sensitive Medicine. <i>European Cardiology Review</i> , 2020, 15, e62.	0.7	3
639	COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. <i>Pulmonologiya</i> , 2020, 30, 688-699.	0.2	18
640	Risk factors for COVID-19 patients with cardiac injury: pulmonary ventilation dysfunction and oxygen inhalation insufficiency are not the direct causes. <i>Aging</i> , 2020, 12, 23464-23477.	1.4	5
641	Editorial: COVID-19 and the quality use of medicines: evidence, risks and fads. <i>Australian Prescriber</i> , 2020, 43, 78-80.	0.5	5
642	Cardiovascular Considerations in Coronavirus Disease 2019 with a Special Focus on Arrhythmia. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020, 11, 4191-4198.	0.2	4
643	Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?. <i>Minerva Cardioangiologica</i> , 2020, 68, 339-346.	1.2	2
644	COVID-19 pandemic and cardiovascular disease: where do we stand?. <i>Minerva Cardioangiologica</i> , 2020, 68, 347-358.	1.2	9
645	Covid-19 Effects on ARTERIAL Stiffness and Vascular Ageing: CARTESIAN Study Rationale and Protocol. <i>Artery Research</i> , 2021, 27, 59.	0.3	19
646	Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, , 4-51.	0.1	20
647	COVID-19 and comorbid chronic diseases. <i>Infusion &amp; Chemotherapy</i> , 2020, , 5-10.	0.0	4
648	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. <i>Frontiers in Physiology</i> , 2020, 11, 596057.	1.3	15
649	Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3136.	1.0	72
650	Risk factors and interventions associated with mortality or survival in adult COVID-19 patients admitted to critical care: a systematic review and meta-analysis. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2020, 26, 116-127.	0.1	9
651	Câncer e DoenÃ§as Cardiovasculares na Pandemia de COVID-19. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 547-557.	0.3	5
652	INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?. <i>Eurasian Heart Journal</i> , 2020, , 64-78.	0.2	2
653	COVID-19 and the kidney. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 619-631.	0.6	52
654	Renin-angiotensin system inhibitors in COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	7
655	Undocumented migrants during the Covid-19 pandemic: social conditions, clinical features and pharmacological treatment. <i>Journal of Public Health Research</i> , 2020, 9, 1852.	0.5	10

#	ARTICLE	IF	CITATIONS
656	Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study. <i>Epidemiology and Health</i> , 2021, 43, e2021004.	0.8	10
657	Hypertension and Electrolyte Disorders in Patients with COVID-19. <i>Electrolyte and Blood Pressure</i> , 2020, 18, 23.	0.6	13
658	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020, 15, 44.	0.9	11
659	COVID-19 and acute kidney injury. <i>Tuberkuloz Ve Toraks</i> , 2020, 68, 407-418.	0.2	30
660	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, , 1-10.	2.3	22
661	MATHEMATICAL MODEL FOR THE INVESTIGATION OF HYPOXIC STATES IN THE HEART MUSCLE AT VIRAL DAMAGE. <i>Biotechnologia Acta</i> , 2021, 14, 38-52.	0.3	0
662	Importance of diabetes management during the COVID-19 pandemic. <i>Postgraduate Medicine</i> , 2021, 133, 912-919.	0.9	8
663	On the problem of the relationship between arterial hypertension and coronavirus disease (COVID-19): literature review. <i>Hypertension</i> , 2021, 14, 40-45.	0.2	0
664	The Treatment of Angiotensin-converting Enzyme Inhibitors in Coronavirus Disease 2019 Patients with Hypertension: A Narrative Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 389-394.	0.1	0
665	Annual reports on hypertension research 2020. <i>Hypertension Research</i> , 2022, 45, 15-31.	1.5	7
666	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
667	Risk and Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Infection on Corneal Transplantation: A Caseâ€“Control Study. <i>Cornea</i> , 2022, 41, 224-231.	0.9	1
668	Quantifying Renin-Angiotensin-System Alterations in COVID-19. <i>Cells</i> , 2021, 10, 2755.	1.8	21
669	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 235-242.	0.9	10
670	COVID-19 and the Incidence of Acute Myocardial Injury. <i>Hamostaseologie</i> , 2021, 41, 356-364.	0.9	6
671	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	1.1	5
672	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
673	Renal involvement in patients with COVID-19. <i>Clinics</i> , 2020, 75, e2194.	0.6	1

#	ARTICLE	IF	CITATIONS
674	Therapeutic Approach to Coronavirus Disease. , 2020, , 67-97.		1
679	Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart. Cardiac Failure Review, 2020, 6, e18.	1.2	1
680	(Treatment with ACE inhibitors and AT1-blockers during the COVID-19 pandemic). Cor Et Vasa, 2020, 62, 27-32.	0.1	0
683	Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019. European Cardiology Review, 2020, 15, e54.	0.7	1
686	COVID-19 ve Hipertansiyon. Turkish Journal of Diabetes and Obesity, 2020, 4, 155-159.	0.0	2
689	COVID-19: Impact in endothelial function and therapy with Mesenchymal Stromal Cells. Magna Scientia UCEVA, 2021, 1, 2-7.	0.1	0
690	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.4	1
691	Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations. Scientific Reports, 2021, 11, 21352.	1.6	10
692	Cardiovascular complications related to COVID-19 disease. Anesthesia: Essays and Researches, 2020, 14, 359.	0.2	2
693	Should we recommend nonsteroidal anti-inflammatory drugs during the COVID-19 pandemic?. ORL Ro, 2020, 4, 46.	0.0	0
694	COVID-19 and the Cardiovascular System: A Review. Wits Journal of Clinical Medicine, 2020, 2, 157.	0.0	0
695	Cardiovascular diseases and complications in patients with COVID-19. Profilakticheskaya Meditsina, 2020, 23, 72.	0.2	1
697	Neprilysin inhibitors and angiotensin(1â€“7) in COVID-19. British Journal of Cardiology, 2020, 27, 109-111.	0.7	3
698	The elderly at risk: aldosterone as modulator of the immune response to SARS-CoV-2 infection. GeroScience, 2022, 44, 567-572.	2.1	8
699	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. Viruses, 2021, 13, 2209.	1.5	36
700	The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience. Cureus, 2020, 12, e10217.	0.2	10
701	Current and future use of angiotensin II receptor blockers in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 28-31.	0.2	0
706	Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic â€“ Do We Have the Evidence?. Journal of Interdisciplinary Medicine, 2020, 5, 105-109.	0.1	0

#	ARTICLE	IF	CITATIONS
709	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. <i>Aging</i> , 2020, 12, 18866-18877.	1.4	0
710	Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection. <i>American Journal of Clinical and Experimental Immunology</i> , 2020, 9, 73-80.	0.2	1
711	Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study. <i>Acta Biomedica</i> , 2020, 91, e2020164.	0.2	16
712	Medication use during COVID-19: Review of recent evidence. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	1
714	Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. <i>Tanaffos</i> , 2020, 19, 274-290.	0.5	5
715	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. <i>Indian Journal of Medical Research</i> , 2021, 153, 7-16.	0.4	4
716	Diabetes and Covid-19: Clinical implications and novel management strategies. <i>Ulster Medical Journal</i> , 2021, 90, 81-85.	0.2	0
717	Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19. <i>Iranian Journal of Medical Sciences</i> , 2021, 46, 312-316.	0.3	0
718	To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients. <i>EXCLI Journal</i> , 2021, 20, 1145-1151.	0.5	1
719	Cardiovascular injuries and SARS-COV-2 infection: focus on elderly people. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 534-548.	0.2	2
720	Coronary calcium score as a predictor of outcomes in the hypertensive Covid-19 population: results from the Italian (S) Core-Covid-19 Registry. <i>Hypertension Research</i> , 2022, 45, 333-343.	1.5	18
721	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
722	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme <sup>2</sup> , Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 772865.	1.5	15
723	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. <i>Nature Communications</i> , 2021, 12, 6791.	5.8	32
724	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 814-817.	0.7	2
725	A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. <i>Journal of Hypertension</i> , 2022, 40, 606-614.	0.3	24
726	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 1-14.	1.0	26
727	Cardiovascular manifestations of COVID-19: An evidence-based narrative review. <i>Indian Journal of Medical Research</i> , 2021, 153, 7.	0.4	11

#	ARTICLE	IF	CITATIONS
728	Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 63-72.	0.5	2
729	COVID-19 and kidney disease. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 726-730.	0.1	0
730	Research strategies in treatment of hypertension: value of retrospective real-life data. <i>European Heart Journal</i> , 2022, 43, 3312-3322.	1.0	11
731	Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 703661.	1.2	19
732	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. <i>Aging</i> , 2020, 12, 18866-18877.	1.4	1
733	VIII. Clinical Features of COVID-19 in the Aspects of Thrombus, Gerontology, and Therapeutics for Hypertension. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 2297-2300.	0.0	0
734	Abstract 15213: Association of Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and Covid-19 Infection Among Patients With Hypertension. <i>Circulation</i> , 2020, 142, .	1.6	0
735	Epidemiological Assessment and Challenges of the COVID-19 Pandemic in Nigeria. <i>Microbiology Research Journal International</i> , 0, , 11-29.	0.2	0
736	Cardiovascular Burden of COVID-19 and the Post-Covid Era. , 2021, 1, 1-10.		0
737	Renin-Angiotensin-Aldosterone System. , 2021, , .		1
738	Cough features during a pandemic. <i>AkademiĀ Mediciny I Sporta</i> , 2022, 2, 37-40.	0.0	0
740	Association of reninĀangiotensinĀaldosterone system inhibition with CovidĀ19 hospitalization and allĀcause mortality in the UK biobank. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2830-2842.	1.1	5
741	Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19. <i>Journal of Tehran University Heart Center</i> , 0, , .	0.2	1
742	Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1073.	1.2	4
743	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 38-48.	1.1	3
744	Stem cells or their exosomes: which is preferred in COVID-19 treatment?. <i>Biotechnology Letters</i> , 2022, 44, 159-177.	1.1	5
745	Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of COVID-19ĀConfirmed Cases and Deaths. <i>American Journal of Cardiology</i> , 2022, 165, 101-108.	0.7	4
746	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	0.7	1

#	ARTICLE	IF	CITATIONS
747	Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes. <i>Vascular Pharmacology</i> , 2022, 143, 106955.	1.0	3
748	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	1.0	0
749	Association of Angiotensin Receptor Blockers With the Risk of COVID-19 in Korea. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	1.0	1
750	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2022, , .	0.1	0
751	COVID-19 and the cardiovascular system: an update. <i>American Journal of the Medical Sciences</i> , 2022, 364, 139-147.	0.4	17
752	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. <i>BMC Medicine</i> , 2022, 20, 52.	2.3	7
753	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. <i>American Heart Journal</i> , 2022, 247, 76-89.	1.2	12
754	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 923-928.	0.2	1
755	The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19. <i>Scientific Reports</i> , 2021, 11, 23670.	1.6	6
756	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
758	Work hours as a risk factor for SARS-CoV-2 infections: cardiometabolic and sleep characteristics in rotating shift workers. <i>Sleep Science</i> , 2022, 15, 380-387.	0.4	4
759	COVID-19 Pandemic: current Challenges and future Perspectives. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 329-337.	0.2	12
760	Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 33-42.	1.3	2
761	Chronic anticoagulant treatment and risk of mortality in SARS-Cov2 patients: a large population-based study. <i>Minerva Medica</i> , 2022, , .	0.3	4
762	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2242.	1.8	17
763	Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 251-264.	2.6	9
764	Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study. <i>BMJ Open</i> , 2022, 12, e058171.	0.8	14
765	Hypertension and COVID-19: Current Evidence and Perspectives. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 115-123.	1.0	44

#	ARTICLE	IF	CITATIONS
766	New Trends in the Diagnosis and Management of Hypertension. <i>Cureus</i> , 2022, 14, e22393.	0.2	2
767	Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment. <i>Biomedicines</i> , 2022, 10, 502.	1.4	10
768	Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	4
769	Coronary artery calcifications and 6-month mortality in patients with COVID-19 without known atheromatous disease. <i>Archives of Cardiovascular Diseases</i> , 2022, , .	0.7	2
770	An Updated Review on Complicated Mechanisms of COVID-19 Pathogenesis and Therapy: Direct Viral Damage, Renin-angiotensin System Dysregulation, Immune System Derangements, and Endothelial Dysfunction. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	3
771	The effect of renin-angiotensin-aldosterone system blockers on the course of COVID-19 in patients with arterial hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2022, 27, 653-661.	0.1	1
772	The Effects of Coronavirus on Human Health and Their Influence on Other Aspects of Life: A Scoping Review. <i>Biosciences, Biotechnology Research Asia</i> , 2022, 19, 47-68.	0.2	1
773	The pathological maelstrom of COVID-19 and cardiovascular disease. , 2022, 1, 200-210.		14
774	COVID-19â€™Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1066-1075.	2.8	30
775	Coronavirus-A Crippling Affliction to Humans. <i>Recent Patents on Biotechnology</i> , 2022, 16, .	0.4	2
776	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. <i>American Heart Journal</i> , 2022, 249, 86-97.	1.2	8
777	Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 46, 101373.	3.2	22
778	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. <i>Kidney International Supplements</i> , 2022, 12, 48-62.	4.6	10
779	Impact of the postâ€™COVIDâ€™19 condition on health care after the first disease wave in Lombardy. <i>Journal of Internal Medicine</i> , 2022, 292, 450-462.	2.7	18
780	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. <i>American Heart Journal</i> , 2022, 247, 15-23.	1.2	40
781	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 792804.	1.1	1
782	COVID-19 and RAAS inhibitors: is there a final conclusion?. <i>Iranian Journal of Microbiology</i> , 2021, 13, 728-736.	0.8	1
783	Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19. <i>Scientific Reports</i> , 2021, 11, 24397.	1.6	5



#	ARTICLE	IF	CITATIONS
784	Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 732690.	2.2	34
785	Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. <i>Journal of Hypertension</i> , 2022, 40, 666-674.	0.3	4
786	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 397-406.	1.4	10
787	Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. <i>Pathobiology</i> , 2022, 89, 166-177.	1.9	4
788	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
789	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of the American Heart Association</i> , 2021, 10, e023535.	1.6	15
790	Why Does the Severity of COVID-19 Differ With Age?. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e36-e45.	1.1	49
791	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. <i>Drugs</i> , 2022, 82, 43-54.	4.9	7
792	EFFECT OF COVID-19 ON CARDIOVASCULAR DISEASES ACCORDING TO LITERATURE. <i>World Science</i> , 2021, , .	0.0	0
793	Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat. <i>Environmental Science and Pollution Research</i> , 2021, , 1.	2.7	2
795	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: which class of drugs should be preferable for patients with cardiovascular pathology?. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 31-46.	0.1	0
796	Hypertension management during the COVID-19 pandemic: what can we learn for the future?. <i>Blood Pressure</i> , 2022, 31, 47-49.	0.7	3
797	Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients. <i>PLoS ONE</i> , 2022, 17, e0266922.	1.1	7
798	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. <i>Nature Reviews Nephrology</i> , 2022, 18, 485-498.	4.1	36
799	Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy. <i>Vaccines</i> , 2022, 10, 623.	2.1	2
809	Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2895-2904.	2.8	4
812	Pre-admission beta-blocker therapy and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2022, 22, .	0.2	1
814	Medication use during COVID-19. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	6

#	ARTICLE	IF	CITATIONS
815	MÃ©dicaments utilisÃ©s durant la COVID-19. Canadian Family Physician, 2021, 67, e69-e78.	0.1	0
816	Cardiac complications of COVID-19: Incidence and outcomes. Indian Heart Journal, 2022, 74, 170-177.	0.2	6
817	Safety of ACEi and ARB in COVID-19 management: A retrospective analysis. Clinical Cardiology, 2022, 45, 759-766.	0.7	9
818	Hybrid Deep Learning Techniques for Predicting Complex Phenomena: A Review on COVID-19. AI, 2022, 3, 416-433.	2.1	11
819	Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells. International Journal of Molecular Sciences, 2022, 23, 5125.	1.8	11
820	Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs. Blood Pressure, 2022, 31, 80-90.	0.7	4
821	The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data. Clinical and Experimental Hypertension, 2022, , 1-5.	0.5	0
823	Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19. Hypertension Research, 2022, 45, 1147-1153.	1.5	11
824	A Review of the Potential of Artificial Intelligence Approaches to Forecasting COVID-19 Spreading. AI, 2022, 3, 493-511.	2.1	13
825	Hourly Analysis of Mechanical Ventilation Parameters in Critically Ill Adult Covid-19 Patients: Association with Mortality. Journal of Intensive Care Medicine, 0, , 088506662211054.	1.3	2
826	Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. Journal of the American Heart Association, 2022, 11, .	1.6	12
827	Hypertension: The most common chronic health problem in Spain. A call to action. Hipertension Y Riesgo Vascular, 2022, , .	0.3	4
828	Opioid-Use, COVID-19 Infection, and Their Neurological Implications. Frontiers in Neurology, 2022, 13, .	1.1	2
829	p53/NF- $\kappa$ B Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics). Frontiers in Pharmacology, 0, 13, .	1.6	18
830	Outcome prediction during an ICU surge using a purely data-driven approach: A supervised machine learning case-study in critically ill patients from COVID-19 Lombardy outbreak. International Journal of Medical Informatics, 2022, 164, 104807.	1.6	7
831	Vulnerability Predictors of Post-Vaccine SARS-CoV-2 Infection and Disease- Empirical Evidence from a Large Population-Based Italian Platform. Vaccines, 2022, 10, 845.	2.1	0
832	Association Between the LZTFL1 rs11385942 Polymorphism and COVID-19 Severity in Colombian Population. Frontiers in Medicine, 0, 9, .	1.2	11
833	Immune system changes in those with hypertension when infected with SARS-CoV-2. Cellular Immunology, 2022, 378, 104562.	1.4	2

#	ARTICLE	IF	CITATIONS
834	COVID-19 and chronic kidney disease: peculiarities of treatment. Ukrainian Journal of Nephrology and Dialysis, 2022, , 83-89.	0.0	0
835	DEMODIALIASIS AND COVID-19 (ANALYSIS OF THE FIRST YEAR OF THE PANDEMIC IN MAKHACHKALA). Nephrology (Saint-Petersburg), 2022, 26, 85-92.	0.1	0
837	Reninâ€“Angiotensinâ€“Aldosterone Inhibitors and COVID-19 Infection. Current Hypertension Reports, 0, , .	1.5	8
838	The effect of reninâ€“angiotensinâ€“aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies. Journal of Intensive Medicine, 2022, 2, 282-290.	0.8	2
839	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. Pharmaceuticals, 2022, 15, 739.	1.7	6
840	Out to the tissues. , 2022, , 89-98.		0
841	Resurgence of hypertension and cardiovascular diseases in patients recovered from COVID-19: An Indian perspective. Journal of Family Medicine and Primary Care, 2022, 11, 2589.	0.3	0
842	Hunting for protective drugs at the break of a pandemic: Causal inference from hospital data. Statistical Methods in Medical Research, 0, , 096228022210984.	0.7	0
843	Đ•Ñ–Đ°ÑfĐ²Đ°Đ½Đ½Ñ•Đ°Ñ€Ñ,ĐµÑ€Ñ–Đ°Đ»ÑCED½Đ¾Ñ– Đ³Ñ–ĐµÑ€Ñ,ĐµÑ€Ñ–Đ½Ñ–Ñ– Đ½Đ°ÑÑfÑ†Đ°ÑĐ½Đ¾Đ½Ñf ĐµÑ,Đ°Ñ		
844	The influence of the pandemic on fear of contagion, blood pressure management and adherence to medication in hypertensive older adults in Turkey. Journal of Human Hypertension, 2022, 36, 852-859.	1.0	4
845	COVIDMED â€“ An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. Contemporary Clinical Trials Communications, 2022, 29, 100968.	0.5	5
846	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Critical Pathways in Cardiology, 2022, 21, 123-129.	0.2	3
847	Immunomodulatory therapies for COVID-19. Frontiers in Medicine, 0, 9, .	1.2	3
848	Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Respiratory Medicine,the, 2022, 10, 900-915.	5.2	34
849	Lack of Correlation Between Soluble Angiotensin-Converting Enzyme 2 and Inflammatory Markers in Hospitalized COVID-19 Patients with Hypertension. Infection and Drug Resistance, 0, Volume 15, 4799-4807.	1.1	0
850	Factors associated with severe or fatal clinical manifestations of SARSâ€“CoVâ€“2 infection after receiving the third dose of vaccine. Journal of Internal Medicine, 0, , .	2.7	3
851	Reninâ€“Angiotensin System Inhibitors in Patients With COVIDâ€“19: A Metaâ€“Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. Journal of the American Heart Association, 2022, 11, .	1.6	26
852	Consequences of COVID-19 on the cardiovascular and renal systems. Sleep Medicine, 2022, 100, 31-38.	0.8	2

#	ARTICLE	IF	CITATIONS
853	Network-Based Data Analysis Reveals Ion Channel-Related Gene Features in COVID-19: A Bioinformatic Approach. <i>Biochemical Genetics</i> , 0, , .	0.8	1
854	COVID-19 Impact on Host at Pathophysiological and Cellular Level. , 2022, , 67-111.		1
855	COVID-19 and Cardiovascular Manifestations. , 2022, , 102-136.		0
856	Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-21.	2.4	6
857	Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-10.	0.8	1
859	COVID-19 in sub-intensive care unit: An Italian single-center experience along the three epidemic waves. <i>Emergency Care Journal</i> , 2022, 18, .	0.2	0
861	The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	22
862	Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6121.	1.0	7
863	Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. <i>Medicina (Lithuania)</i> , 2022, 58, 1554.	0.8	1
864	Drug Development Strategies and Immunological Aspects of SARS-CoV-2. <i>Open Public Health Journal</i> , 2022, 15, .	0.1	2
865	Impact of Hypertension on COVID-19 Burden in Kidney Transplant Recipients: An Observational Cohort Study. <i>Viruses</i> , 2022, 14, 2409.	1.5	2
866	Use of chronic medications and risk of severe death due to COVID-19 in hospitalised patients. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2021-003186.	0.5	2
867	Troponin in COVID-19: To Measure or Not to Measure? Insights from a Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5951.	1.0	1
868	Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 619-634.	1.4	2
869	Coronavirus disease 2019 and cardiovascular disease: what we have learnt during the last 2 years. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 710-714.	0.6	1
870	Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank. <i>PLoS ONE</i> , 2022, 17, e0276781.	1.1	4
871	Mitochondrial Effects of Common Cardiovascular Medications: The Good, the Bad and the Mixed. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13653.	1.8	12
872	Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. <i>Biochemical Pharmacology</i> , 2023, 208, 115370.	2.0	7

#	ARTICLE	IF	CITATIONS
873	Damage to the cardiovascular system and complications in Covid-19 infection with a focus on the post-acute covid19 syndrome. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 104-118.	0.0	0
875	Metabolic syndrome and aberrant immune responses to viral infection and vaccination: Insights from small animal models. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
876	Developing a comorbidity score in cancer patients using healthcare utilization databases during the COVID-19 pandemic: An experience from Italy. <i>Cancer Medicine</i> , 0, , .	1.3	0
878	COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. <i>Hypertension Research</i> , 2023, 46, 589-600.	1.5	14
879	Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping. <i>Health Data Science</i> , 2022, 2022, .	1.1	4
880	COVID-19 and Antihypertensive Treatment. <i>Contemporary Cardiology</i> , 2022, , 303-316.	0.0	0
881	Immunomodulatory Properties of Nutraceuticals and Functional Foods. , 2022, , 21-72.		0
882	Acute Vascular Injury in COVID-19. <i>Contemporary Cardiology</i> , 2022, , 151-170.	0.0	0
883	Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications. <i>Systemic Hypertension</i> , 2023, 19, 37-44.	0.1	1
885	The effect of COVID-19 on the in-hospital outcomes of percutaneous coronary intervention in patients with acute coronary syndrome: A large scale meta-analysis. , 2023, 9, 100032.		1
886	Blood pH and COVID-19. <i>Archiv Der Pharmazie</i> , 2023, 356, .	2.1	1
887	A Retrospective Study on Prevalence and Profile of Reverse Transcriptase Polymerase Chain Reaction Positive Severe Acute Respiratory Syndrome Corona Virus 2 Samples Tested in a Tertiary Care Hospital, South India. <i>Apollo Medicine</i> , 2023, 20, S1-S6.	0.0	0
888	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. <i>Oxford Open Immunology</i> , 2023, 4, .	1.2	3
889	Emerging Novel Therapies for COVID-19: Implications for the Use of Nitric Oxide as an Anti-COVID-19 Therapy. , 2023, , 259-278.		0
890	Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease. <i>Life</i> , 2023, 13, 536.	1.1	4
892	Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. <i>Nature Genetics</i> , 2023, 55, 471-483.	9.4	14
893	COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination. <i>Vaccines</i> , 2023, 11, 693.	2.1	3
894	Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2

#	ARTICLE	IF	CITATIONS
895	Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact. Internal and Emergency Medicine, 2023, 18, 801-809.	1.0	3
897	BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial. MBio, 2023, 14, .	1.8	12
898	Clinical and social determinants of health features of SARS-CoV-2 infection among Black and Caribbean Hispanic patients with heart failure: The SCAN-MP Study. PLoS ONE, 2023, 18, e0283730.	1.1	0
899	Patients with COPD hospitalized due to COVID-19 in Spain: a comparison between the first and second wave. Revista Clínica Española, 2023, , .	0.3	1
900	Hypertension clinical care in the era of coronavirus disease 2019. Heart India, 2023, 11, 19-27.	0.2	0
901	Post-Exposure Prophylaxis for COVID-19: A Systematic Review. Infectious Disorders - Drug Targets, 2023, 23, .	0.4	1
902	Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review. Biomedicines, 2023, 11, 1206.	1.4	5
905	Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review. Cardiovascular Drugs and Therapy, 0, , .	1.3	11
914	Diabetes and COVID. Contemporary Cardiology, 2023, , 1025-1041.	0.0	0
922	Mitigating secondary disaster triggered by fear of COVID-19: the role of professional medical societies. Hypertension Research, 2024, 47, 559-561.	1.5	0
926	Pharmacotherapeutics for cytokine storm in COVID-19. , 2024, , 101-125.		0